Mayne Pharma | MYX - Gross Profit On Sales

Stock Price
4.66
Daily Change
0.16 3.56%
Monthly
-6.80%
Yearly
-2.51%
Q3 Forecast
5.25

Mayne Pharma reported AUD115.99M in Gross Profit on Sales for its fiscal semester ending in June of 2024.



Financials
Stock Price AUD
Assets AUD 1.14B
Cash and Equivalent AUD 110.07M
Cost of Sales AUD 43.74M
Current Assets AUD 460.59M
Current Liabilities AUD 313.94M
Debt AUD 38.82M
Dividend Yield 0
EBIT AUD -16.2M
EBITDA AUD -65.76M
Employees 900
EPS Earnings Per Share AUD -0.89
Equity Capital and Reserves AUD 454.19M
Gross Profit on Sales AUD 115.99M
Interest Expense on Debt AUD 1.2M
Loan Capital AUD 31.64M
Market Capitalization AUD 382.83M
Net Income AUD -103.68M
Operating Expenses AUD 103.54M
Operating Profit AUD -3.3M
Ordinary Share Capital AUD 1.22B
Pre-Tax Profit AUD -57.61M
Sales Revenues AUD 195.04M
Selling and Administration Expenses AUD 54.8M
Stock AUD 74.63M
Trade Creditors AUD 20.87M
Trade Debtors AUD 193.22M

Gross Profit On Sales Change Date
Ansell USD 326.2M 27.6M Jun/2024
Avita Medical AUD 16.13M 3.05M Dec/2024
Cochlear AUD 881.7M 14.5M Dec/2024
CSL USD 4.28B 939M Dec/2024
Healius AUD 554.4M 415.55M Dec/2024
Integral Diagnostics AUD 226.91M 7.04M Jun/2024
Medical Developments International AUD 14.72M 1.36M Dec/2024
Nanosonics AUD 73.44M 38.94M Dec/2024
Next Science USD 9.48M 511.44K Dec/2024
Polynovo AUD 23.26M 22.74M Jun/2024
Ramsay Health Care AUD 6.32B 20.5M Dec/2024
ResMed USD 829.44M 78.16M Jun/2025
Sigma Healthcare AUD 160.13M 10.55M Jul/2024
Sonic Healthcare AUD 3.92B 3.14B Dec/2024
Telix Pharmaceuticals AUD 129.12M 96.58M Dec/2024